Share on StockTwits

Eleven Biotherapeutics (NASDAQ:EBIO) major shareholder Jafco Super V3 Investment Limi sold 1,165 shares of the stock in a transaction dated Wednesday, August 20th. The shares were sold at an average price of $11.54, for a total transaction of $13,444.10. Following the completion of the transaction, the insider now directly owns 2,121,526 shares in the company, valued at approximately $24,482,410. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Major shareholders that own more than 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Shares of Eleven Biotherapeutics (NASDAQ:EBIO) traded up 1.42% on Friday, hitting $11.40. 768 shares of the company’s stock traded hands. Eleven Biotherapeutics has a one year low of $9.502 and a one year high of $19.333. The stock has a 50-day moving average of $11.89 and a 200-day moving average of $12.96. The company’s market cap is $175.5 million.

Eleven Biotherapeutics (NASDAQ:EBIO) last announced its earnings results on Wednesday, August 13th. The company reported ($0.51) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.47) by $0.04. On average, analysts predict that Eleven Biotherapeutics will post $-1.84 earnings per share for the current fiscal year.

Eleven Biotherapeutics, Inc, is a United States-based company, which develops protein-based biotherapeutics.

Receive News & Ratings for Eleven Biotherapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eleven Biotherapeutics Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.